Steven Cohen's ARQT Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 590,877 shares of Arcutis Biotherapeutics, Inc. (ARQT) worth $13.92 M, representing 0.02% of the portfolio. First purchased in 2020-Q3, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in ARQT, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2022, adding 1.8 M shares. Largest reduction occurred in Q4 2022, reducing 2.68 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Arcutis Biotherapeutics (ARQT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arcutis Biotherapeutics (ARQT) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +165,725 | Add 38.98% | 590,877 | $23.56 |
| Q4 2025 | +425,152 | New Buy | 425,152 | $29.04 |
| Q3 2025 | -1.49 M | Sold Out | 0 | $0.00 |
| Q2 2025 | +654,947 | Add 78.86% | 1.49 M | $14.02 |
| Q1 2025 | -923,044 | Reduce 52.64% | 830,478 | $15.64 |
| Q4 2024 | +1.51 M | Add 617.52% | 1.75 M | $13.93 |
| Q3 2024 | +244,386 | New Buy | 244,386 | $9.30 |
| Q1 2024 | -320,300 | Sold Out | 0 | $0.00 |
| Q4 2023 | +320,300 | New Buy | 320,300 | $3.23 |
| Q1 2023 | -1.1 M | Sold Out | 0 | $0.00 |
| Q4 2022 | -2.68 M | Reduce 70.85% | 1.1 M | $14.80 |
| Q3 2022 | +1.8 M | Add 90.46% | 3.79 M | $19.11 |
| Q2 2022 | +289,582 | Add 17.06% | 1.99 M | $21.31 |
| Q1 2022 | -946,328 | Reduce 35.79% | 1.7 M | $19.26 |
| Q4 2021 | +652,070 | Add 32.73% | 2.64 M | $20.74 |
| Q3 2021 | +1.1 M | Add 122.23% | 1.99 M | $23.89 |
| Q2 2021 | +457,100 | Add 104.05% | 896,400 | $27.29 |
| Q1 2021 | -435,900 | Reduce 49.81% | 439,300 | $28.93 |
| Q4 2020 | +831,944 | Add 1923.30% | 875,200 | $28.13 |
| Q3 2020 | +43,256 | New Buy | 43,256 | $29.29 |
Steven Cohen's Arcutis Biotherapeutics Investment FAQs
Steven Cohen first purchased Arcutis Biotherapeutics, Inc. (ARQT) in Q3 2020, acquiring 43,256 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Arcutis Biotherapeutics, Inc. (ARQT) for 20 quarters since Q3 2020.
Steven Cohen's largest addition to Arcutis Biotherapeutics, Inc. (ARQT) was in Q3 2022, adding 3,785,277 shares worth $72.34 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 590,877 shares of Arcutis Biotherapeutics, Inc. (ARQT), valued at approximately $13.92 M.
As of the Q1 2026 filing, Arcutis Biotherapeutics, Inc. (ARQT) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Arcutis Biotherapeutics, Inc. (ARQT) was 3,785,277 shares, as reported at the end of Q3 2022.